IDEAYA Biosciences Inc. Common Stock
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients with solid tumors having MTAP deletions; PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
IDYA Overview
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$21.6200 |
Previous Close Volume |
254010 |
Latest News
- IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma 17 Dec 2024 06:25:09
- IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers 16 Dec 2024 06:23:36
- IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 11 Dec 2024 06:24:30
- IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer 10 Dec 2024 06:25:09
- IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor 09 Dec 2024 06:25:37
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 06 Dec 2024 06:25:28
- IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events 02 Dec 2024 06:25:59
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 29 Nov 2024 06:25:17
- IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer 18 Nov 2024 06:25:30
- IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day 12 Nov 2024 06:25:16
- IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen 11 Nov 2024 06:25:52
-
/C O R R E C T I O N -- IDEAYA Biosciences, Inc./
04 Nov 2024 08:32:49
https://media.ideayabio.com/2024-11-04-C-O-R-R-E-C-T-I-O-N-IDEAYA-Biosciences,-Inc
- IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update 04 Nov 2024 06:02:32
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 01 Nov 2024 06:17:36
- IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors 28 Oct 2024 06:02:30
- IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024 25 Oct 2024 06:25:42
- IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium 04 Oct 2024 06:25:47
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 27 Sep 2024 06:25:57
- IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma 23 Sep 2024 06:17:37
- IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024 22 Sep 2024 09:02:41
- IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel 18 Sep 2024 06:02:41
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 30 Aug 2024 06:24:59
- IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference 26 Aug 2024 06:25:36
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 23 Aug 2024 06:24:23
- IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update 06 Aug 2024 06:25:57
- IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen 31 Jul 2024 06:10:51
- IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event 29 Jul 2024 06:41:03
- IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants 09 Jul 2024 16:26:10
- IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer 08 Jul 2024 06:26:03
- IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024 05 Jul 2024 16:26:04
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 28 Jun 2024 06:26:20
- IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer 25 Jun 2024 06:26:09
- IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors 24 Jun 2024 06:26:12
- IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study 03 Jun 2024 06:26:08
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 31 May 2024 06:26:14
- IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events 29 May 2024 06:03:36
- IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development 28 May 2024 06:41:04
- IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma 23 May 2024 17:11:15
- IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update 07 May 2024 06:11:16
- IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event 01 May 2024 06:11:12
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 26 Apr 2024 06:26:21
- IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study 24 Apr 2024 10:26:23
- IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer 22 Apr 2024 06:26:19
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 05 Apr 2024 06:11:23
- IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event 01 Apr 2024 06:11:26
- IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer 12 Mar 2024 06:11:26
- IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events 04 Mar 2024 06:11:25
- IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update 20 Feb 2024 06:11:32
- IDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events 01 Feb 2024 06:11:33
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 26 Jan 2024 06:11:25